Search for other papers by Germán A. Jimenez Londoño in
Google Scholar
PubMed
Search for other papers by Ana Maria Garcia Vicente in
Google Scholar
PubMed
Search for other papers by Julia Sastre Marcos in
Google Scholar
PubMed
Search for other papers by Francisco Jose Pena Pardo in
Google Scholar
PubMed
Search for other papers by Mariano Amo-Salas in
Google Scholar
PubMed
Search for other papers by Manuel Moreno Caballero in
Google Scholar
PubMed
Search for other papers by Maria Prado Talavera Rubio in
Google Scholar
PubMed
Search for other papers by Beatriz Gonzalez Garcia in
Google Scholar
PubMed
Search for other papers by Niletys Dafne Disotuar Ruiz in
Google Scholar
PubMed
Search for other papers by Angel Maria Soriano Castrejón in
Google Scholar
PubMed
the real endpoints. Thus, different systems have been used to predict the prognosis of patients with thyroid cancer. Recently, the 2015 American Thyroid Associations (ATA) guidelines have added a dynamic risk assessment system, which classifies the
Search for other papers by Marie Alix Balay in
Google Scholar
PubMed
Search for other papers by Patrick Aidan in
Google Scholar
PubMed
Search for other papers by Marie Helene Schlageter in
Google Scholar
PubMed
Search for other papers by Odette Georges in
Google Scholar
PubMed
Search for other papers by Taly Meas in
Google Scholar
PubMed
Search for other papers by Maroun Bechara in
Google Scholar
PubMed
Search for other papers by Marie Elisabeth Toubert in
Google Scholar
PubMed
Search for other papers by Isabelle Faugeron in
Google Scholar
PubMed
Search for other papers by Herve Monpeyssen in
Google Scholar
PubMed
Search for other papers by Cécile N. Chougnet in
Google Scholar
PubMed
Thyroid Association (ATA) guidelines [ 2 ] for the management of thyroid cancer changed in 2015: they now advocate a more appropriate and risk-adapted approach to both the diagnosis and treatment of thyroid cancer. Regarding RAI therapy, the lowest
Search for other papers by Shirley Langham in
Google Scholar
PubMed
Search for other papers by Peter Hindmarsh in
Google Scholar
PubMed
Search for other papers by Steven Krywawych in
Google Scholar
PubMed
Developmental Endocrinology Research Group, Institute of Child Health, University College London, London, UK
Search for other papers by Catherine Peters in
Google Scholar
PubMed
To allow comparison with the UKNSPC guidelines, TSH values >20 mU/l are presented as positive and 10-19.9 mU/l as borderline on the first screen. These cut-off points were then compared to the additional information generated by operating the GOSH
Search for other papers by Enrico Papini in
Google Scholar
PubMed
Search for other papers by Hervé Monpeyssen in
Google Scholar
PubMed
Search for other papers by Andrea Frasoldati in
Google Scholar
PubMed
Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
the highest possible level of evidence derived from studies carried out in a European setting. These guidelines address the optimization of the use of innovative therapeutic tools in clinical management of benign thyroid nodules. They address the
Search for other papers by Roberto Negro in
Google Scholar
PubMed
Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed
Search for other papers by Roberto Attanasio in
Google Scholar
PubMed
Search for other papers by Enrico Papini in
Google Scholar
PubMed
Search for other papers by Kristian H. Winther in
Google Scholar
PubMed
use in mild GO is recommended in current ETA guidelines [ 29 , 30 ]. An Italian survey, published in 2016, investigated the clinical use of Se supplementation in the index case of a 42-year-old female patient with GD. In the absence of GO, only 20% of
Search for other papers by Bjarke Borregaard Medici in
Google Scholar
PubMed
Search for other papers by Jeppe Lerche la Cour in
Google Scholar
PubMed
Search for other papers by Luba Freja Michaelsson in
Google Scholar
PubMed
Search for other papers by Jens Oscar Faber in
Google Scholar
PubMed
Search for other papers by Birte Nygaard in
Google Scholar
PubMed
Background Hypothyroidism is a common disease that affects primarily women with a range of symptoms. Levothyroxine (L-T 4 ) is the mainstay replacement therapy of choice according to guidelines, but some patients report persistent hypothyroid
Search for other papers by Irene Campi in
Google Scholar
PubMed
Search for other papers by Marco Dell’Acqua in
Google Scholar
PubMed
Search for other papers by Elisa Stellaria Grassi in
Google Scholar
PubMed
Search for other papers by Maria Cristina Vigone in
Google Scholar
PubMed
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
robust and accurate biomarker to diagnose primary thyroid dysfunctions, and accordingly, the guidelines endorsed by several scientific societies recommend a reflex TSH testing strategy as a first-line screen for thyroid dysfunction in the general
Search for other papers by Jingyue Chen in
Google Scholar
PubMed
Search for other papers by Chenyan Li in
Google Scholar
PubMed
Search for other papers by Weiping Teng in
Google Scholar
PubMed
Search for other papers by Zhongyan Shan in
Google Scholar
PubMed
Search for other papers by Jun Jin in
Google Scholar
PubMed
Search for other papers by Yining Wei in
Google Scholar
PubMed
Search for other papers by Jing Sun in
Google Scholar
PubMed
Search for other papers by Yushu Li in
Google Scholar
PubMed
Search for other papers by Huifang Zhou in
Google Scholar
PubMed
guidelines for GO ( 9 ). The guidelines were updated in 2021 ( 10 ). In 2022, the American Thyroid Association (ATA) and the ETA jointly published a consensus statement for TED ( 11 ). These guidelines and consensus statements provide reliable and
Search for other papers by María de los Ángeles Garayalde Gamboa in
Google Scholar
PubMed
Search for other papers by Melina Saban in
Google Scholar
PubMed
Search for other papers by Marina Ines Curriá in
Google Scholar
PubMed
be used as an alternative therapy. However, there are no guidelines or consensus about the correct use of parenteral LT4, and there are very few studies assessing the effectiveness and safety of parenteral LT4 as an alternative to oral LT4. On the
Search for other papers by Sophie Demartin in
Google Scholar
PubMed
Search for other papers by Stefan Matei Constantinescu in
Google Scholar
PubMed
Search for other papers by Kris G Poppe in
Google Scholar
PubMed
Search for other papers by Dominique Maiter in
Google Scholar
PubMed
Search for other papers by Raluca Maria Furnica in
Google Scholar
PubMed
Search for other papers by Orsalia Alexopoulou in
Google Scholar
PubMed
Search for other papers by Chantal Daumerie in
Google Scholar
PubMed
Search for other papers by Frederic Debiève in
Google Scholar
PubMed
Search for other papers by Maria-Cristina Burlacu in
Google Scholar
PubMed
Introduction Hypothyroidism diagnosed during pregnancy, whether subclinial or overt, is associated with adverse pregnancy and neonatal outcomes ( 1 ). Existing guidelines unanimously recommend the treatment of overt hypothyroidism (OH) in this